Is NCT07325240 recruiting in Rochester, MN?

Yes, NCT07325240 is currently recruiting participants at its Rochester, MN location. This open angle glaucoma clinical trial is actively enrolling qualified participants.

How do I join the open angle glaucoma clinical trial in Rochester?

To join this clinical trial in Rochester, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Rochester clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Open Angle Glaucoma Clinical Trial in Rochester, MN

About This Open Angle Glaucoma Study in Rochester

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

Sponsor: Mayo Clinic

Who Can Participate

Inclusion Criteria

Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit.

Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit

Be able and willing to provide signed informed consent and follow study instructions

Ability to cooperate with the examinations required for the study and be able to attend all study visits

If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits.

Best-corrected visual acuity (BCVA) using ETDRS chart of +0.4 logMAR units (Snellen equivalent \~ 20/50) or better in each eye

Exclusion Criteria

Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye

Severe glaucomatous damage

Difference in IOP between eyes \> 4 mmHg (unmedicated) at any baseline time point

Use of more than two ocular hypotensive medications within 30 days of screening

Chronic or recurrent inflammatory eye diseases in either eye

Ocular infection or ocular inflammation in the past 3 months in either eye

Ocular trauma other than corneal abrasion within the past 6 months in either eye

Clinically significant retinal disease (e.g., severe diabetic retinopathy, exudative or severe non-exudative macular degeneration, macular edema, retinal vein or artery occlusion) in either eye

Cornea pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, keratoconus) in either eye

Myopia greater than -6.00D, or hyperopia greater than +2.00D in either eye

Central corneal thickness less than 480 μm or greater than 620 μm in either eye

Previous intraocular surgery other than routine uncomplicated cataract surgery in either eye

Previous glaucoma intraocular surgery or glaucoma laser procedures (except SLT performed more than 6 months ago) in either eye

Unilateral intraocular surgery or glaucoma laser procedures

Previous corneal refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking, etc.)

Severe dry eye in either eye

Use of ocular medications in either eye within 30 days of screening, with the exception of IOP-lowering medications (which must be washed out according to the provided schedule), and lubricating drops for dry eye (which may be used throughout the study)

Known hypersensitivity to any component of the formulation (eg, benzalkonium chloride, etc.), or to topical anesthetic Systemic:

Clinically significant systemic diseases which might interfere with the study

Participation in any interventional study within 30 days prior to screening visit

Changes of systemic medication that could have an effect on IOP within 30 days prior to screening, or anticipated during the study including, β-adrenergic antagonists, α-adrenergic agonists and antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers

Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including: systemic/inhaled steroids, calcium channel blockers, diuretics, and vasodilators

Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative pregnancy test result at the screening examination and must not intend to become pregnant during the study

Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT07325240) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Open Angle Glaucoma Treatment Options in Rochester, MN

If you're searching for open angle glaucoma treatment options in Rochester, MN, this clinical trial (NCT07325240) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced open angle glaucoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all open angle glaucoma clinical trials near you to find additional studies recruiting in your area.

Open Angle Glaucoma Clinical Trial in Rochester, MN

Expert Care in Rochester

IRB Approved

No-Cost Care

Apply for This Rochester Location

Why Participate?

Simple Process